期刊文献+

胰岛素联合罗格列酮或二甲双胍治疗对2型糖尿病患者血清hCRP的影响 被引量:1

Effects of insulin plus rosiglitazone or plus metformin on serum high C reaction protein in type 2 diabetes mellitus.
下载PDF
导出
摘要 目的了解胰岛素联合罗格列酮或二甲双胍治疗对2型糖尿病患者血清hCRP水平的影响。方法将符合纳入标准的2型糖尿病患者60例,随机分成A,B两组。A组给予胰岛素联合罗格列酮(4mg/d,n=30)治疗,B组给予胰岛素联合二甲双胍治疗(n=30),共8周,治疗前后分别测空腹血糖、餐后2h血糖、糖化血红蛋白及血清hCRP等。结果胰岛素联合罗格列酮或二甲双胍治疗,均能降低血糖和糖化血红蛋白(P<0.05)。治疗前后,罗格列酮组hCRP水平降低了1.8mg/L,二甲双胍组hCRP水平降低了0.9mg/L,但均未达到统计学意义(P>0.05)。结论罗格列酮或二甲双胍在胰岛素治疗2型糖尿病患者的基础上,对血清hCRP水平进一步降低作用不明显。 Objective To observe the effects of insulin plus rosiglitazone and insulin plus meffomain on serum high C reaction protein(hCRP) in type 2 diabetes mellitus. Methods Sixty type 2 diabetic patients were recruited and divided into group A and group B randomly. Group A( n = 30) received insulin plus rosiglitazone(4mg/d), group B(n = 30) received insulin plus meffomain. The trial consisted for an 8 week course of treatment. The fasting blood glucose(FBG), postprandial plasma glucose(PPG), HbA1c and serum hCRP were measured at the beginning and at the end of the trial. Results The results showed the level of FBG, PPG and HbA1 c decreased obviously( P 〈 0.05) in boty insulin plus rosiglitazone group and insulin plus meffomain group. Compared with baseline, the mean level of hCRP decreased 1.8mg/L in rosiglitazone group, and 0.9mg/L in meffomain group, respectively, but the deference has not statistical significance( P 〉 0.05 ). Conclusion Rosiglitazone or meffomain can not decrease tile level of serum hCRP in type2 diabetes mellitus on the basis of insulin therapy.
出处 《四川医学》 CAS 2007年第11期1200-1201,共2页 Sichuan Medical Journal
基金 2006年四川省卫生厅科研基金资助项目(WST060098)
关键词 2型糖尿病 胰岛素 罗格列酮 二甲双胍 联合治疗 hCRP type 2 diabetes mellitus insulin rosiglitazone meffomain united treatment high C reaction protein(hCRP)
  • 相关文献

参考文献8

二级参考文献36

  • 1何冰,韩萍,吕先科.2型糖尿病患者急性时相蛋白与糖尿病肾病的关系[J].中华内分泌代谢杂志,2003,19(4):260-262. 被引量:170
  • 2[1]Haffner SM. Do interventions to reduce coronary heart disease reduce the incidence of type 2 diabetes? a possible role for inflammatory factors. Circulation, 2001, 103(3): 346-347.
  • 3[2]Greenberg A, Haffner SM, Weston W, et al. Rosiglitazone reduces c-reactiveprotein, amarkerofsystematicinflammation, intype2diabeticpatients. Diabetologia, 2001, 44(Supple 1 ): A853-A860.
  • 4[3]Zimmet PZ. Diabetes epidemiology as a tool to trigger diabetes research and care. Diabetologia, 1999, 42 (5): 499-518.
  • 5[4]LevinSR, CoburnJW, AbrairaC, etal. Effect of intensive glycemic controlon microalbuminuria in type 2 diabetes. Diabetes Care, 2000, 23 (10):1478-1485.
  • 6[5]Kinlay S, Selwyn AP, Libby P, et al. Inflammation, the endothelium,and the acute coronary syndromes. J Cardiovasc Pharmacol, 1998, 32(Suppl 3): S62-S66.
  • 7[6]Saito 1, Folsom AR, Brancati FL, et al. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities Study. Ann Intern Med, 2000, 133(2): 81-91.
  • 8[7]Danesh J, Collins R, Appleby P, et al. Association of fibrinogen,c-reactive protein, albumin, or leukocyte count with coronary heart disease: meat-analyses of prospective studies. JAMA, 1998, 279(18):1477-1482.
  • 9Hong G, Davis B, Khatoon N, et al. PPARgamma-dependent anti-inflammatory action of rosiglitazone in human monocytes: suppression of TNFalpha secretion is not mediated by PTEN regulation[J]. Biochem Biophys Res Commun, 2003, 303(3): 782-787
  • 10Liu HR, Tao L, Gao E, et al. Pro-inflammatory Effects of Hypercholesterolemia and Anti-inflammatory Effects of a Peroxisome Proliferator-activated Receptor-gamma (PPAR) Agonist[J]. Acad Emerg Med, 2003, 10(5):558-559

共引文献61

同被引文献11

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部